5-Amino-1MQ (NNMT inhibitor)

Discovery and background

5-Amino-1MQ (systematically 5-amino-1-methylquinolinium) is a small-molecule, membrane-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT, EC 2.1.1.1). NNMT catalyzes transfer of a methyl group from the cofactor S-adenosyl-L-methionine (SAM) to nicotinamide (vitamin B3), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Long regarded mainly as a hepatic nicotinamide-clearance route, the enzyme has emerged as a nodal regulator of cellular metabolism at the intersection of NAD+ turnover, the methyl pool and epigenetic methylation ^[1].

Interest in pharmacological NNMT suppression rose sharply after work in which antisense knockdown of NNMT in high-fat-diet mice protected against fat-mass gain and improved energy-metabolism markers in white adipose tissue and liver ^[2]. These genetic data motivated the search for selective small-molecule inhibitors. 5-Amino-1MQ became one of the first described membrane-permeable tools of this class: it reversibly inhibits human and mouse NNMT in a cellular context and reproduces part of the knockdown metabolic phenotype in diet-induced obesity models ^[3].

Structure and physicochemical properties

The molecular core is a quinolinium (benzo[b]pyridinium) cation, a bicyclic aromatic system with a positively charged quaternary nitrogen methylated at N1 and an amino group at position 5. The cation has the formula C10H11N2(+) and a molar mass of about 159.21 g/mol; commercially the compound is usually a salt (most often the iodide, C10H11IN2, ~286.11 g/mol). The permanent positive charge of the quaternary nitrogen makes the structure resemble the nicotinamide/methylpyridinium motif, explaining its affinity for the NNMT active site ^[4].

As a permanently charged organic cation, 5-Amino-1MQ is readily soluble in water and polar aprotic solvents (DMSO) and crystallizes as a solid. The primary amino group (5-NH2) provides a hydrogen-bond donor and a protonation site; its electron-donating character modulates the aromatic ring's electron density. The key distinction of this chemotype from earlier bisubstrate NNMT inhibitors is its ability to cross the plasma membrane, which makes it suitable for cell-based rather than only cell-free (enzymatic) experiments ^[3][4].

Molecular mechanism of action

NNMT is a cytosolic SAM-dependent methyltransferase of the class I Rossmann-like fold. Crystallographic studies of human NNMT revealed two binding pockets: the SAM cofactor site and an adjacent substrate site that recognizes nicotinamide via an aromatic sandwich and specific hydrogen bonds; catalysis proceeds by direct SN2 methyl transfer to the pyridine nitrogen of nicotinamide ^[5]. As a methylquinolinium cation, 5-Amino-1MQ is a structural mimic of product/substrate and competes for the substrate (nicotinamide) site, lowering the rate of 1-MNA formation.

The biochemical significance follows from NNMT acting as a "methyl sink": the active enzyme continuously consumes SAM and generates SAH and the stable, slowly cleared metabolite 1-MNA. In tumor cells with high NNMT expression this forms a metabolic methylation sink that depletes the SAM pool and remodels the epigenetic landscape of histones and DNA ^[6]. Inhibiting the enzyme with 5-Amino-1MQ theoretically shifts the SAM/SAH balance toward restoring the cell's methylation potential.

Metabolic and signaling consequences

Because nicotinamide is a precursor in the NAD+ salvage pathway, NNMT-mediated methylation of nicotinamide competes with its recycling through nicotinamide phosphoribosyltransferase (NAMPT) back into NAD+. Excess NNMT activity diverts nicotinamide into a methylated dead-end product, whereas enzyme suppression is proposed to preserve substrate for NAD+ resynthesis and support cellular redox and energy status ^[7]. NAD+ is simultaneously a substrate for sirtuins and PARPs, so changes in its availability have branching signaling consequences.

The second vector is the methyl pool. Through the SAM/SAH couple, NNMT suppression affects the global methylation potential, bearing on histone and DNA methylation and other SAM-dependent reactions ^[8]. The metabolite 1-MNA is itself a signaling molecule with reported effects on lipid metabolism and vascular biology, so reducing its production is also part of the inhibition phenotype. Together these axes make NNMT a point of integration between energy metabolism and epigenetic regulation ^[8].

Preclinical research: obesity and metabolism

The most studied direction for 5-Amino-1MQ is metabolic. In a high-fat-diet mouse model of obesity, systemic administration of membrane-permeable NNMT inhibitors of this series was associated with reduced body and fat mass, smaller adipocytes and improved metabolic parameters without lowered food intake: the effect was thus attributed to increased expenditure/adipose remodeling rather than an anorectic action ^[3]. These findings recapitulated key features of genetic NNMT knockdown ^[2].

Independent groups developed other structural classes of small-molecule NNMT inhibitors and showed, in preclinical rodent models of metabolic disease, reduced tissue 1-MNA and SAH together with favorable metabolic changes, validating the target as pharmacologically tractable ^[9]. Structure-activity relationship (SAR) work around the methylquinolinium/methylpyridinium scaffold delineated determinants of potency, selectivity and membrane permeability, in which the combination of a charged heterocycle with substituents that tune substrate-pocket binding is central ^[4].

NNMT in oncology and fibrosis

Beyond metabolism, NNMT is a focus of cancer research. The enzyme is frequently overexpressed in tumors (kidney, lung, stomach, colon and others), where it creates a methyl sink and promotes epigenetic remodeling and an aggressive phenotype ^[6]. Its role in the tumor microenvironment is especially notable: proteomic analysis identified NNMT as a master metabolic regulator of cancer-associated fibroblasts (CAFs), where it depletes SAM, lowers methylation and sustains a pro-oncogenic secretory program of the stroma ^[10]. Tool inhibitors such as 5-Amino-1MQ are therefore used to dissect the contribution of NNMT to these processes in vitro and in preclinical models.

Pharmacokinetics and metabolism

The systemic pharmacokinetics of 5-Amino-1MQ in humans are not established; available data are limited to preclinical species. As a permanently charged cation the compound has limited passive lipophilicity, yet its reported membrane permeability is sufficient for intracellular inhibitory action, likely with the participation of organic cation transporters (OCTs). Because the molecule is a quinolinium analogue, it is not a substrate of NNMT for methylation in the same sense as nicotinamide; the detailed routes of its biotransformation and excretion remain under investigation. The information here concerns characterization of the compound as a reagent and is not guidance for human use.

Related compounds and analogues

5-Amino-1MQ belongs to a family of methylated azinium (pyridinium/quinolinium) cations related to the natural NNMT product 1-methylnicotinamide (1-MNA) and the model substrate analogue 1-methylquinolinium (1-MQ). The amino group at position 5 distinguishes it from unmodified 1-MQ and improves the enzyme-interaction profile. The broader field of NNMT inhibitors includes bisubstrate analogues (spanning both the SAM and nicotinamide pockets), SAH-based derivatives, and other small-molecule chemotypes developed in SAR programs ^[4][9]. Comparing these classes allows separation of the contributions of cofactor versus substrate binding.

Analytical characterization (HPLC/MS, purity)

Identity and purity of 5-Amino-1MQ in research practice are confirmed by a combination of methods. Reversed-phase HPLC (C18, with ion-pairing or acidic aqueous-acetonitrile gradients and UV detection at the characteristic absorbance of the quinolinium chromophore) is used to assess chromatographic purity (typically ≥98%). High-resolution mass spectrometry (ESI+) confirms the [M]+ cation at nominal m/z ~159 (C10H11N2+). The structure is established by (1)H and (13)C NMR, revealing signals for the N-methyl, the aromatic quinolinium protons and the amino group; for salts the counterion identity (e.g., iodide) is additionally controlled. Batch certificates of analysis (CoA) usually accompany the reagent ^[4].

Handling, reconstitution chemistry and storage

As a hygroscopic organic salt, 5-Amino-1MQ is stored in tightly closed containers protected from moisture and light at low temperature (typically −20 °C for long-term storage of the solid). To prepare stock solutions in the laboratory the compound is usually dissolved in water or DMSO owing to its cationic nature; aqueous solutions of aminoaromatic salts can oxidize slowly, so they are prepared fresh, aliquoted, and repeated freeze-thaw cycles are avoided. Work follows practices for fine organic reagents (personal protective equipment, fume hood when weighing). This concerns laboratory handling of the reagent and is not instruction for any in vivo human use.

Research applications and model systems

In the research toolkit, 5-Amino-1MQ serves as a chemical probe for NNMT inhibition across a wide range of systems: adipocyte cultures (3T3-L1) and preadipocyte differentiation, primary and immortalized tumor lines with high NNMT expression, CAF models, hepatocytes and skeletal myocytes, and rodent models of metabolic disease ^[3][9][10]. Typical readouts include 1-MNA and SAM/SAH levels (as direct markers of enzymatic activity), NAD+/NADH, lipolysis and substrate uptake, and histone/DNA methylation profiles ^[6][8]. Combining genetic (NNMT knockdown/knockout) and pharmacological (5-Amino-1MQ) approaches provides orthogonal target validation. All described applications are preclinical and laboratory-based; the material is for research use only (RUO) and has no approved clinical use in humans.